Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

471
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
471
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

397
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
397
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unintentional fatal overdose of veterinary levamisole in a human subject.

Journal of forensic sciences·2026
Same author

Evidence-Based Toxicology-Hypothesis Testing in Randomized Clinical Trials: Part I-Superiority.

Journal of medical toxicology : official journal of the American College of Medical Toxicology·2026
Same author

Evidence-Based Toxicology-Hypothesis Testing in Randomized Clinical Trials: Part II-Equivalence.

Journal of medical toxicology : official journal of the American College of Medical Toxicology·2026
Same author

Evidence-Based Toxicology-Hypothesis Testing in Randomized Clinical Trials: Part III - Non-Inferiority.

Journal of medical toxicology : official journal of the American College of Medical Toxicology·2025
Same author

Level of care following suspected opioid or stimulant overdose with self-harm intent.

The American journal of emergency medicine·2025
Same author

Normal physiologic carboxyhemoglobinemia of neonate masquerading as carbon monoxide poisoning.

The American journal of emergency medicine·2025
Same journal

Articles You Might Have Missed.

Journal of medical toxicology : official journal of the American College of Medical Toxicology·2026
Same journal

Botulism Type F, a Rare Type of Botulism that Can Masquerade as a Posterior Fossa Stroke.

Journal of medical toxicology : official journal of the American College of Medical Toxicology·2026
Same journal

An ACMT Network of Medical Toxicology Clinics (NMTC): A Proposed Collaboration of Medical Toxicologists to Meet National Emergency Preparedness Needs.

Journal of medical toxicology : official journal of the American College of Medical Toxicology·2026
Same journal

Medical Toxicology is the Overdose Specialty: Implications for the Dimensions and Continuum of Overdose Care.

Journal of medical toxicology : official journal of the American College of Medical Toxicology·2026
Same journal

Responsiveness of the 2024-2030 ACMT Research Agenda to New Funding Priorities and Research Environment.

Journal of medical toxicology : official journal of the American College of Medical Toxicology·2026
Same journal

A Narrative Summary of Strategies to Mitigate Intradialytic Hypotension in Poisoned Patients Requiring Extracorporeal Toxin Elimination.

Journal of medical toxicology : official journal of the American College of Medical Toxicology·2026
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K

Apixaban Overdose with Massive Bleeding and Anti-Xa Levels.

Rebecca Kusko1,2, Jami Hagemann3, Daniel McCabe3,4,5

  • 1Department of Emergency Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, 52242, USA. Rebecca-kusko@uiowa.edu.

Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology
|April 13, 2026
PubMed
Summary
This summary is machine-generated.

Overdosing on apixaban (a factor Xa inhibitor) can cause severe bleeding, requiring aggressive treatment. Drug levels decrease predictably, even at high doses, aiding in patient management.

Keywords:
ApixabanCase ReportDirect Oral AnticoagulantHemorrhageOverdose

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.8K

Related Experiment Videos

Last Updated: Apr 15, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.8K

Area of Science:

  • Pharmacology
  • Toxicology
  • Internal Medicine

Background:

  • Factor Xa inhibitors, like apixaban, are increasingly used.
  • Overdose cases are rare, with unclear bleeding risk and drug level behavior.

Purpose of the Study:

  • To report a case of massive bleeding following a significant apixaban overdose.
  • To analyze the elimination kinetics of apixaban at supratherapeutic levels.

Main Methods:

  • A 70-year-old male with polysubstance overdose, including >250 mg apixaban, presented with severe GI hemorrhage and subdural hematoma.
  • Treatment involved tranexamic acid (TXA), anti-inhibitor coagulant complex (FEIBA), and massive transfusion.
  • Serial anti-Xa levels were monitored until undetectable.

Main Results:

  • The patient experienced no further bleeding after aggressive treatment.
  • Apixaban elimination followed a first-order pattern, even at markedly supratherapeutic concentrations.

Conclusions:

  • Life-threatening hemorrhage can occur with factor Xa inhibitor overdose, necessitating intensive supportive care.
  • Apixaban elimination kinetics are predictable, even in overdose scenarios.